Industry | 卫生和社会工作业 | ||||||||||||||||||||||||
Company Introduction | 中珠医疗控股股份有限公司原是中国眼科药业第一家上市公司,主要生产经营滴眼剂、针剂、片剂等六大剂型及化学原料药等150多个品种品规,公司曾被国务院发展研究中心评定为"中国最大的眼科用药生产厂家".2009年9月5日,公司与控股股东中珠股份进行资产置换及非公开发行股份的重组事项完成,公司除保留相当规模的医药类资产的同时,置入优质的房地产及商品混凝土业务,目前形成以房地产、医药为主业的双主业经营格局。 | ||||||||||||||||||||||||
Main Business | 药品的研发、生产和销售;肿瘤治疗领域相关产 品生产及销售;住宅地产开发 | ||||||||||||||||||||||||
Legal Representative | 陈旭 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 张卫滨 | ||||||||||||||||||||||||
Solicitors | 北京市天元律师事务所 | ||||||||||||||||||||||||
Auditors | 立信会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 0728-6402068 | ||||||||||||||||||||||||
Fax No | 0728-6402099 | ||||||||||||||||||||||||
Website | www.zz600568.com | ||||||||||||||||||||||||
zz600568@126.com | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 18/05/2001 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ -0.170 | ||||||||||||||||||||||||
DPS(RMB)* | -- | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 1.231 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 2.270B |
Only Chinese content is avaliable | |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |